SCH-1473759
CAS No. 1094069-99-4
SCH-1473759 ( SCH1473759 | SCH 1473759 )
产品货号. M10365 CAS No. 1094069-99-4
Aurora A 和 B 的有效皮摩尔双重抑制剂,IC50 分别为 0.02 和 0.03 nM;显示出改善的细胞效力(phos-HH3 抑制 IC50=25 nM)和固有水溶性(11.4 mM)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥1774 | 有现货 |
|
| 50MG | ¥6051 | 有现货 |
|
| 100MG | ¥9234 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称SCH-1473759
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Aurora A 和 B 的有效皮摩尔双重抑制剂,IC50 分别为 0.02 和 0.03 nM;显示出改善的细胞效力(phos-HH3 抑制 IC50=25 nM)和固有水溶性(11.4 mM)。
-
产品描述A potent, picomolar, dual inhibitor of Aurora A and B with IC50 of 0.02 and 0.03 nM, respectively; shows improved cell potency (phos-HH3 inhibition IC50=25 nM) and intrinsic aqueous solubility (11.4 mM); emonstrated efficacy and target engagement in human tumor xenograft mouse models.
-
体外实验SCH-1473759 directly binds to aurora A and B with Kds of 20 and 30 nM, respectively. SCH-1473759 also inhibits the Src family of kinases (IC50<10 nM), Chk1 (IC50=13 nM), VEGFR2 (IC50=1 nM), and IRAK4 (IC50=37 nM). It does not have significant activity (IC50>1000 nM) against 34 other kinases representing different families of the kinome. SCH-1473759 inhibits HCT116 cells proliferation with an IC50 of 6 nM. SCH 1473759 inhibits tumor cell lines from different tissues (breast, ovarian, prostate, lung, colon, brain, gastric, renal, skin, and leukemia). The most sensitive cell lines includ A2780, LNCap, N87, Molt4, K562, and CCRF-CEM with IC50 values <5 nM.
-
体内实验SCH-1473759 at a low dose of 5 mg/kg (ip, bid) is well-tolerated in a continuous dosing schedule and shows 50% tumor growth inhibition(TGI) on day 16. A higher dose of 10mg/kg(ip, bid) is well-tolerated in an intermittent schedule (5 days on, 5 days off) and gave 69% TGI on day 16. SCH-1473759 shows good exposure in all species with the clearance being high in rodents and moderate in dog and monkey. The half-life is also moderate, but the tissue distribution is high. SCH 1473759 dose- and schedule-dependent anti-tumor activity in four human tumor xenograft models. Further, the efficacy is enhanced in combination with taxanes and found to be most efficacious when SCH 1473759 is dosed 12-h post-taxane treatment.
-
同义词SCH1473759 | SCH 1473759
-
通路Cell Cycle/DNA Damage
-
靶点Aurora Kinase
-
受体Aurora Kinase
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1094069-99-4
-
分子量426.5385
-
分子式C20H26N8OS
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESCC(C)(N(CC)CC1=NSC(NC2=NC(C)=CN3C2=NC=C3C4=CNN=C4)=C1)CO
-
化学全称1-Propanol, 2-[ethyl[[5-[[6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-isothiazolyl]methyl]amino]-2-methyl-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Yu T, et al. ACS Med Chem Lett. 2010 Jun 7;1(5):214-8.
2. Basso AD, et al. Cancer Chemother Pharmacol. 2011 Oct;68(4):923-33.
产品手册
关联产品
-
PHA-680632
一种有效的、高选择性的 Aurora 激酶抑制剂,对 Aurora A、B 和 C 的 IC50 值分别为 27、135 和 120 nM。
-
Pilaralisib
Pilaralisib 是一种口服小分子,可选择性抑制磷酸肌醇 3 激酶 (PI3K) 的活性。
-
Ilorasertib hydrochl...
Ilorasertib (ABT-348) hydrochloride 是一种有效的,具有口服活性和 ATP 竞争性的 aurora 抑制剂,对 aurora A, aurora B, aurora C 的 IC50 值分别为 116, 5, 1 nM。Ilorasertib hydrochloride 也是一种有效的 VEGF 和 PDGF 抑制剂。Ilorasertib hydrochloride 具有用于急性髓系白血病 (AML) 和骨髓增生异常综合征 (MDS) 的研究潜力。
021-51111890
购物车()
sales@molnova.cn

